loratadine (claritin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.   NCATS

Chemistry

  • SMILES: CCOC(=O)N1CCC(CC1)=C2C3=CC=C(Cl)C=C3CCC4=C2N=CC=C4
  • InChIKey: JCCNYMKQOSZNPW-UHFFFAOYSA-N
  • Mol. Mass: 382.883
  • ALogP: 4.89
  • ChEMBL Molecule:
    loratadine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.0168 - $2.1300

Australia

$0.5014 - $0.9045
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( loratadine (claritin), pseudoephedrine (Benylin) - other name: claritin-d 24 hour )

Alternative names

alavert | children's claritin | claritin | claritin-d | claritin hives relief | claritin hives relief reditab | claritin reditabs | clarityn | clarityne | clarityn rapide | hay-rite | loracert | loradex | loratadina | loratadine | loratadine redidose | loratadinum | loratidine | loratyne | roletra | sch-29851

Organizations (78)

Research & Development (51)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (31)

Approved Indications (2)


 

Rhinitis, Allergic (approved 1993)

Rhinitis, Allergic, Seasonal

Experimental Indications - Clinical Trial Phases 1-4 (31)


 

Arthritis, Rheumatoid (Phase 1)

Asthma (Phase 3)

Back Pain (Phase 2)

Breast Neoplasms (Phase 2)

Chronic Urticaria (Phase 2)

Common Cold (Phase 3)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 4)

COVID-19 (Phase 2/Phase 3)

Dermatitis, Atopic (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Eosinophilic Esophagitis (Phase 2)

Healthy Volunteers (Phase 4)

Hematopoietic Stem Cell Transplantation (Phase 2)

Histamine H1 Antagonists, Non-Sedating (Phase 1)

Hypersensitivity ()

Kidney Transplantation (Phase 2)

Lymphangioleiomyomatosis (Phase 2)

Lymphoma (Early Phase 1)

Multiple Myeloma (Early Phase 1)

Multiple Sclerosis (Phase 1)

Pain (Phase 2)

Pharmacology, Clinical (Phase 1)

Pruritus (Phase 4)

Quality of Life (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal ()

Uremia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 67
  • # of Trial Organizations: 51

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue